Caring Deeply. Changing Lives

We measure success by our impact on patients we serve

Neurotrope BioScience, Inc. (NTRP:NASDQ), formed in 2012, is at the forefront of biotechnology companies having a focus on developing new therapies for the treatment of rare diseases (Orphan diseases) and Alzheimer’s Disease.

Our experience, capabilities and passion for innovative patient care have enabled us to build a pipeline that includes therapies for serious and difficult to treat neurodegenerative diseases.

NTRP has also teamed up with Stanford University to find the next generation Bryostatin – Bryologs.

NTRP is also progressing the other licensed asset from BRNI – a new, non-invasive diagnostic test for early stage Alzheimer’s Disease.